MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy

IMPORTANCE OF THE FIELD

The challenge in breast cancer vaccine development is to find the best combination of antigen, adjuvant and delivery system to produce a strong and long-lasting immune response. Mucin 1 (MUC1) is a potential candidate target for breast cancer immunotherapy. Bacillus Calmette-Guerin (BCG) is used widely in human vaccines. Furthermore, it can potentially offer unique advantages for developing a safe and effective multi-vaccine vehicle. Due to these properties, the development of MUC1 based recombinant BCG (rBCG) vaccines for breast cancer immunotherapy has gained great momentum in recent years.

AREAS COVERED IN THIS REVIEW

Our aim is to discuss the recent progress in MUC1-based breast cancer immunotherapy and to highlight the advantages of MUC1-based rBCG vaccines as the new breast cancer vaccines.

WHAT THE READER WILL GAIN

Several promising MUC1-based rBCG vaccines have been shown to induce MUC1-specific antitumor immune responses in pre-clinical studies. This review updates and evaluates this very important and rapidly developing field, and provides a critical perspective and information source for its potential clinical applications.

TAKE HOME MESSAGE

MUC1-based rBCG vaccines have been shown to elicit an effective anti-tumor immune response in vivo demonstrating its potential utility in breast cancer treatment.

Towards improved understanding of protective mechanisms induced by the BCG vaccine

EVALUATION OF: Ryan AA, Nambiar JK, Wozniak TM et al. Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette-Guérin vaccine or Mycobacterium tuberculosis infection. J. Immunol. 182(11), 7172-7177 (2009). Mycobacterium tuberculosis is the causative agent of human TB, which is responsible for 26% of all preventable deaths in the developing world. Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used as a vaccine against TB since 1921, with protection varying from 0 to 80%. Although the reasons for this variability are unclear, protection is thought to be mediated by Th1-type responses. CD8(+) T cells have been shown to play a role in the response to mycobacteria. However, the nature of the CD8(+) response induced by BCG requires further characterization. In the paper being evaluated, it was shown that the antigenic load is important for the induction of CD8(+) T-cell responses and subsequent protective responses. Identification of the factors affecting induction of CD8(+) responses against mycobacteria will facilitate studies to characterize their nature and provide a platform for the development of systems seeking to improve on protection conferred by BCG.

The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses

Mycobacterium bovis BCG is still the most widely used vaccine against tuberculosis and CD8(+) T cells play important roles in fighting infection. We investigated how well antigen is processed and presented to CD8(+) T cells using the same well-characterized CD8(+) T cell epitope SIINFEKL expressed in either a cytoplasmic (GFP-OVA) or secreted (85B-OVA) context from BCG. We report that secreted SIINFEKL from 85B-OVA BCG is presented better than cytoplasmic SIINFEKL expressed by GFP-OVA BCG.

How do mycobacteria activate CD8+ T cells?

CD8(+) T cells are activated upon presentation of antigens from the cytosol. Therefore, it was unclear how pathogenic mycobacteria could prime this type of lymphocyte, given that these microbes were thought to remain in phagosomes and, hence, be shielded from the host cytosol. Recently, it was shown that some mycobacteria can enter the cytosol through translocation from phagolysosomes, providing a direct mechanism for CD8(+) T cell priming. However, this mechanism might not apply to other mycobacteria, which do not appear to be able to enter the cytosol. Here, we discuss the different hypotheses to explain the induction of CD8(+) T cell responses in mycobacterial infections.